Objective. TNF-a-induced protein 3 (TNFAIP3) is one of the major SLE susceptibility genes involved in the regulation of inflammatory responses through modulation of the nuclear factor-kB (NF-kB) pathway. We aim to assess TNFAIP3 expression in CD4 + T cells and the molecular mechanism underlying TNFAIP3 regulation in the pathogenesis of SLE.
Introduction
SLE is an archetypical systemic, autoimmune inflammatory disease characterized by dysregulated activation of T cells and excessive production of autoantibodies targeting to multiple nuclear components [1] . T-Cell dysfunction contributes to activate auto-reactive B cells and aggravate inflammatory injury of target organs by excessive secretion of inflammatory cytokines and therefore plays a key role in the pathogenesis of SLE [2, 3] . Thus, an understanding of the molecular defects in T cells and the potential dysregulated pathways may be of significance for unravelling the underlying pathogenesis and identifying potential therapeutic targets of SLE.
Accumulating evidence has demonstrated that aberrant epigenetic modification play a pivotal role in triggering the dysregulation of T-cell activation, leading to the incidence of SLE [4] . DNA hypomethylation in CD4
+ T cells appears to induce overexpression of autoimmune-associated genes, such as CD11a, CD70 and CD40L, thus contributing to the onset and development of SLE [57] . In addition, global histone H3 and H4 hypoacetylation in active lupus CD4 + T cells and global histone H3K9 hypomethylation in both active and inactive lupus CD4 + T cells have been more frequently observed compared with healthy controls [8] . However, the exact role of aberrant epigenetic modification involved in the pathogenesis of SLE remains elusive.
It has been widely recognized that the transcription factor nuclear factor-kB (NF-kB) plays a crucial role in regulating the expression levels of a variety of inflammatory cytokines and chemokines [9] . Overactivation of NFkB has been proved to be involved in the incidence of multiple inflammatory and autoimmune diseases [10] . TNF-a-induced protein 3 (TNFAIP3, also known as A20) is an ubiquitin-editing enzyme that has been shown to be a negative regulator of NF-kB in various signalling pathways [11] . TNFAIP3-deficient B cells in aged mice are found to present with impaired differentiation and hyperactivation, thereby resulting in inflammation and autoimmunity [12] . In addition, the expression level of TNFAIP3 is significantly downregulated in peripheral blood mononuclear cells (PBMCs) of SLE patients, and single nucleotide polymorphisms in the enhancer elements of TNFAIP3 are intimately correlated with the genetic predisposition of SLE [13] . SLE-related single nucleotide polymorphisms of TNFAIP3 may be one mechanism underlying its defect in terms of both expression and function. Nevertheless, whether epigenetic modifications are involved in regulating TNFAIP3 expression and the exact role of TNFAIP3 in the pathogenesis of SLE remain to be elucidated.
In the present study, CD4 + T cells were isolated from SLE patients and healthy controls for quantitative analysis of the mRNA transcription of TNFAIP3. DNA methylation and histone modification on the promoter region of the TNFAIP3 gene was measured for evaluation of the epigenetic regulation on gene expression. 
RNA isolation and RT-PCR
Total RNA was isolated from CD4 + T cells using the RNeasy mini kit (Qiagen, Valencia, CA, USA). Firststrand cDNAs were synthesized using RevertAid firststrand cDNA synthesis kit (Fermentas, Burlington, ON, Canada) with 0.5 mg of total RNA according to the manufacturer's instructions. Real-time quantitative PCR (qPCR) was performed using a Rotor-Gene 3000 (Corbett Research, Mortlake, NSW, Australia), and mRNA levels were quantified using the QuantiTect SYBR Green qPCR Kit (Qiagen, Valencia, CA, USA). b-Actin was amplified and used as a loading control. Primer sequences used for qPCR are listed in Table 1 .
Western blot
Proteins were extracted from CD4 + T cells and separated by SDSPAGE using 12% polyacrylamide gels. Proteins were then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA), and blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) buffer and incubated with antibodies against TNFAIP3 diluted at a ratio of 1:300 (Santa Cruz Biotechnology, Dallas, TX, USA) or b-actin at a dilution ratio of 1:10000 (Santa Cruz Biotechnology, Dallas, TX, USA). Band intensity was quantified using Quantity One software (Bio-Rad, Hercules, CA, USA).
Genomic DNA extraction, bisulphite conversion and promoter sequencing
Genomic DNA was isolated from CD4 + T cells using TIANamp genomic DNA blood kit (Tiangen Biotech, Beijing, China). Bisulphite conversion was then performed by using the EpiTect bisulphite kit (Qiagen, Venlo, The Netherlands). The CpG islands in the promoter region ($2000 bp upstream of transcription start site) of TNFAIP3 were predicted using an online software package, MethPrimer (http://www.urogene.org/methprimer/). DNA fragments from the two CpG islands in TNFAIP3 promoter region, one located at À607 to À758 bp from transcription start site (TSS), with a length of 151 bp (CpG1), and the other one located at À531 bp to +234 bp from TSS, with a length of 765 bp (CpG2), were amplified in two cycles of nested PCR, using the primers listed in Table 1 . Subsequently, the fragments were cloned into a pGEM T vector (Promega, Madison, WI, USA), and 10 independent clones were sequenced from each fragment by Sanger sequencing on an ABI3730 (Applied Biosystems, Foster city, CA, USA).
Chromatin immunoprecipitation and qPCR
Chromatin immunoprecipitation (ChIP) analysis was performed using the ChIP assay kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. In brief, CD4 + T cells were fixed with 37% formaldehyde for 10 min at room temperature. Glycine was then added to a final concentration of 0.125 M to quench the formaldehyde. Cells were pelleted, washed twice with ice-cold PBS and lysed. Lysates were pelleted, resuspended, and sonicated to reduce DNA to 200 $1000 bp fragments.
Fragmented chromatins were incubated with or without 2 mg of monoclonal antibodies against human H3Ac, H3K4me3 or H3K9me3 (Abcam, Cambridge, MA, USA) at 4 C overnight. The chromatinantibody complexes were then precipitated with protein-A agarose beads, washed, and eluted in 250 ml eluting buffer (mixed 10% SDS with 0.1 M NaHCO 3 to 1:9). Precipitated DNA was subsequently purified with phenol/chloroform extraction and ethanol. The targeting DNA was subjected to realtime qPCR analysis using RT2 SYBR Green qPCR Master mixes (Qiagen, Germantown, MD, USA) and the following primers: ChIP-forward: 5 0 -CAGCCCAAACTTTTC AGAGC-3 0 ; and ChIP-reverse:
Knockdown of TNFAIP3 by siRNA in CD4 + T cells
The TNFAIP3 siRNA and non-silencing siRNA constructs were purchased from Invitrogen (Invitrogen, Carlsbad, CA, USA). Three siRNA constructs (siRNA-1, siRNA-2 and siRNA-3) were tested in this study, and siRNA-1, which exhibited the strongest interfering effect on TNFAIP3 expression, was selected for the functional experiment. CD4 + T cells from HCs were transiently transfected with TNFAIP3 siRNA constructs or control plasmid using human T-cell nucleofector kit and Amaxa nucleofector (Lonza, Basel, Switzerland). Transfected cells were cultured in human T-cell culture medium and harvested 48 h later. The extent of siRNA-mediated inhibition of TNFAIP3 expression was measured by western blotting. The effect of TNFAIP3 silencing on the expression of inflammatory cytokines was evaluated by qPCR and ELISA. The sequences of three siRNAs were as follows:
0 ; and TNFAIP3-siRNA-3: 
Results

TNFAIP3 was significantly decreased in CD4 + T cells of SLE patients
Participant demographics are shown in supplementary Table S1 , available at Rheumatology Online. All SLE patients enrolled in this study were newly diagnosed, with no history of anti-lupus treatment before admission. The expression levels of TNFAIP3 at both mRNA and protein levels in the CD4 + T cells from 15 SLE patients and 15
NCs were quantitatively measured by RT-PCR and western blot. The results revealed that the expression of TNFAIP3 mRNA and TNFAIP3 protein was significantly downregulated in the CD4 + T cells from SLE patients compared with those from NCs, as illustrated in Fig. 1 . We also analysed the correlation of TNFAIP3 expression with the clinical manifestations in SLE patients (SLEDAI score, nephritis, arthritis). The expression levels of TNFAIP3 in CD4 + T cells of SLE patients were not significantly associated with SLEDAI score (supplementary Fig. S1 , available at Rheumatology Online) or other clinical phenotype (P > 0.05; data not shown).
DNA methylation was not changed on the CpG islands of TNFAIP3 promoter region in CD4 + T cells of SLE patients
To assess whether decreased TNFAIP3 expression in SLE patients was correlated with aberrant DNA methylation, we analysed the DNA methylation in the promoter region of the TNFAIP3 gene in CD4 + T cells from SLE patients and NCs using bisulphate-specific PCR. As revealed in Fig. 2A , two CpG islands were predicted in the promoter region of TNFAIP3 gene using the MethPrimber software; the first one, designed as CpG1, was located in À758 to À 607 bp, and the second one, CpG2, was situated in À531 to +234 bp upstream of TSS. The mean methylated levels of both CpG islands did not differ significantly between SLE patients and HCs (P < 0.05), as illustrated in Fig. 2B and C. H3K4me3 was decreased in TNFAIP3 promoter of SLE CD4 + T cells Next, we investigated the effect of histone modification on the expression of TNFAIP3 in SLE patients. The levels of H3Ac, H3K4me3 and H3K9me3 associated with the promoter region of the TNFAIP3 genomic loci in CD4 + T cells from SLE patients and HCs were measured quantitatively using ChIP-qPCR. As shown in Fig. 3 , the level of H3K4me3 in the promoter region of the TNFAIP3 gene was significantly lower in SLE patients compared with HCs, whereas the levels of H3Ac and H3K9me3 at the TNFAIP3 genomic loci were not significantly differ between SLE patients and HCs (Fig. 3) . Our data suggested that the decreased expression of the TNFAIP3 gene in CD4 + T cells of SLE patients might result from decreased methylation on histone H3K4 in the TNFAIP3 promoter.
Knockdown of TNFAIP3 upregulated Th1 and Th17 cytokines in CD4 + T cells
To investigate the role of TNFAIP3 in regulating T-cell functions, the effect of TNFAIP3 on production of cytokines in CD4 + T cells was investigated. TNFAIP3 knockdown was conducted specifically in normal CD4 + T cells through siRNA, and the mRNA transcription of IL-2, IFN-, IL-4, IL-5, IL-17A and IL-17F was measured by quantitative RT-PCR. Among the three siRNAs tested, siRNA-1 exhibited the most significant suppressive effect on TNFAIP3 mRNA transcription ( Fig. 4A and B) . siRNA-1-transfected CD4 + T cells revealed significantly higher expression of IFN-, IL-17A and IL-17F mRNA compared with vector-transfected cells (Fig. 4C) . However, the expression levels of IL-2, IL-4 and IL-5 were not www.rheumatology.oxfordjournals.org
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TNFAIP3 downregulation in CD4 + T cells of SLE considerably changed (Fig. 4C) . Furthermore, we detected an increased expression of IFN-g and IL-17 proteins in the culture supernatant of the CD4 + T cells transfected with TNFAIP3-siRNA-1 compared with vector-transfected CD4 + T cells (Fig. 4D) .
Overexpression of TNFAIP3 in SLE CD4 + T cells suppressed Th1 and Th17 cytokine production
To further validate the effect of TNFAIP3 on SLE CD4 + T cells, the TNFAIP3 gene was transiently overexpressed in CD4 + T cells isolated from SLE patients. As shown in exhibited decreased transcription of IFN-, IL-17A and IL-17F compared with NCs, whereas IL-2, IL-4 and IL-5 remained unchanged (Fig. 5C ). The expression of IFN-g and IL-17 proteins was also found to be significantly decreased in cell culture supernatant of CD4 + T cells that overexpressed TNFAIP3 compared with NCs (Fig. 5D ).
Discussion
In this study, we compared the transcription level of TNFAIP3 in CD4 + T cells from SLE patients and NCs and found that SLE patients exhibited significant lower TNFAIP3 expression at both mRNA and protein levels. As far as we know, this is the first report to demonstrate the decreased expression of TNFAIP3 in CD4 + T cells in SLE patients.
TNFAIP3 encodes A20, an ubiquitin-editing enzyme that is expressed in almost all cells and plays a key role in negatively regulating NF-kB pathway activity and protecting cells against TNF-induced programmed cell death [16, 17] . In immune cells, overexpression of A20 could terminate NF-kB signalling transduced from multiple cell surface receptors, such as TNF receptors, Toll-like receptors and T-cell receptors [17, 18] . The function of A20 in limiting immune responses has been well documented in several murine models. Mice deficient in A20 were hypersensitive to both lipopolysaccharide and TNF and experienced severe inflammation, cachexia and premature death [16] . Tavares et al. [19] have reported that A20-deficient B cells were hypersensitive to Toll-like receptor, B-cell receptor and CD40 receptor stimulation, and mice expressing absent or hypomorphic amounts of A20 in B cells possessed elevated quantities of germinal centre B cells, autoantibodies and glomerular immunoglobulin deposits. Genome-wide association studies have suggested that variants in or near the TNFAIP3 gene locus were significantly associated with autoimmune diseases, including SLE [13, 2022] , RA [23, 24] , psoriasis [25, 26] and SSc [27, 28] . Furthermore, it has been reported that the expression of TNFAIP3 is downregulated in the PBMCs of SLE patients [29, 30] . Our study provided further evidence that abnormal expression of TNFAIP3 in CD4 + T cells may contribute to the autoimmune pathogenesis in SLE.
The dysregulation of TNFAIP3 in CD4 + T cells may be associated with genetic variation as well as abnormal epigenetic modification. The genetic variations of the TNFAIP3 locus and their association with SLE have been extensively studied in different populations. Among those variants, a pair of tandem polymorphic dinucleotides (collectively referred to as TT > A), recently nominated as causal variants, was reported to be responsible for genetic association between TNFAIP3 and the occurrence of SLE [20] . An enhancer element harbouring the TT > A variants impaired the binding of the transcription factor NF-kB with the TNFAIP3 promoter and therefore inhibited the expression of A20 [13] . On the contrary, epigenetic modification may also play an important role in the regulation of aberrant gene expression in SLE. Global DNA hypomethylation has been identified to be associated with the overexpression of SLE signature genes in CD4 + T cells and PBMCs [31, 32] . Hypermethylation of the IL-2 gene promoter in SLE CD4 + T cells downregulated the expression level, leading to dysfunction of T cells [33] . In the present study, we first predicted the CpG islands in the promoter region of the TNFAIP3 gene using MethyPrimer software and then measured the DNA methylation status of the CpG islands by bisulphite-specific PCR. Among the two CpG islands in the promoter region of TNFAIP3, none of them showed a significant methylation difference between SLE and NCs, suggesting that the aberrant expression of TNFAIP3 in CD4 + T cells of SLE may not be regulated by a change of DNA methylation in this region. However, the influence of DNA methylation on the www.rheumatology.oxfordjournals.org aberrant TNFAIP3 gene expression could not be excluded, because the DNA methylation may occur in a CpG locus other than the two CpG islands of the promoter region.
Other than DNA methylation, epigenetic regulation of gene expression may also involve histone modification and miRNAs [9, 34] . Previous studies have revealed abnormal patterns of histone modification in the CD4 + T cells in SLE patients and MRL-lpr/lpr mice [8] . In the present study, we measured the levels of histone H3 acetylation (H3Ac) and methylation (H3K4me3 and H3K9me3), which are the most commonly observed patterns of histone modification. Our data indicated that H3K4me3 was significantly reduced in the promoter region of TNFAIP3 in SLE CD4 + T cells compared with that in HCs, whereas the H3Ac and H3K9me3 remained unchanged, suggesting that demethylation of H3K4 may contribute to the reduced expression of TNFAIP3 in CD4 + T cells of SLE patients. In accordance with our finding, Xia et al. [35] reported that Ash1l, an H3K4 methyltransferase, could enhance A20 expression through induction of H3K4 methylation at the TNFAIP3 promoter. They further confirmed that A20-mediated NF-kB suppression attenuated subsequent IL-6 production and prevented the incidence of inflammatory autoimmune diseases [35] . Previous studies have demonstrated that inflammatory cytokines, such as type I interferon, IL-6 and IL-17, were significantly increased in peripheral blood mononuclear cells of SLE patients [32] . The data from the present study, together with others, suggests that H3K4me3 is involved in the regulation of the TNFAIP3NF-kBinflammation pathway and contributes to the pathogenesis of SLE. Abnormal T-cell activation and excessive production of inflammatory cytokines are hallmark features of SLE [36, 37] . To explore whether absent expression of A20 contributes to T-cell dysfunction, we manipulated the expression of TNFAIP3 in normal CD4 + T cells using siRNA.
We found that knocking down TNFAIP3 from normal CD4 + T cells significantly upregulated the expression of IFN-, IL-17A and IL-17F, whereas the expression of IL-2, IL-4 and IL-5 was not significantly affected.
Another experiment was performed to enhance the expression of TNFAIP3 in SLE CD4 + T cells by transient transfection of TNFAIP3 expression vectors, and again we observed the decreased expression of IFN-, IL-17A and IL-17F mRNA as well as reduced levels of IFN-g and IL-17 proteins in the culture supernatant derived from CD4 + T cells overexpressing TNFAIP3. Our data indicated that TNFAIP3 is involved in regulating the secretion of Th1 (IFN-g) and Th17 (IL-17) subset cytokines, which are considered to be key factors in the pathogenesis of SLE. Previous studies have demonstrated that overexpression of TNFAIP3 suppressed the activity of NF-kB and subsequent production of IL-6. Given the fact that IL-6 is one of the stimuli for Th17 cell differentiation [38] , we suggest that decreased expression of TNFAIP3 probably induced Th17 cell differentiation and IL-17 overproduction by mediating the IL-6 signalling pathway.
Conclusion
The downregulation of TNFAIP3 in CD4 + T cells of SLE patients was potentially regulated by demethylation of histone H3K4, which led to the decreased amount of H3K4me3 in the promoter of the TNFAIP3 gene. The dysregulation of TNFAIP3 in CD4 + T cells may contribute to the pathogenesis of SLE by overproduction of the inflammatory cytokines IFN-g and IL-17. TNFAIP3 and the molecules on its regulating pathway may serve as promising targets for the treatment of SLE in clinical practice.
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